Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation

Summary

During orthotopic liver transplantation (OLT) excessive bleeding is the main cause of death and graft failure. The acute bleeding tendency that accompanies OLT, particularly during the anhepatic period and after reperfusion of the graft, is due to the depletion or functional abnormalities of several hemostasis components caused by the enhanced activity of enzymes such as plasmin, trypsin and leukocyte proteases. We surmised that enhanced proteolysis might also cause abnormalities of von Willebrand factor (vWF), and that these abnormalities are implicated in the bleeding tendency that develops during OLT. Therefore, the pattern of vWF proteolysis was studied with 16 patients with chronic liver disease, in serial blood samples obtained before OLT, during the anhepatic stage, after graft reperfusion and at the end of the surgical procedure. vWF became markedly degraded during the anhepatic and reperfusion stages, as shown by the partial loss of high molecular weight multimers, the relative decrease of the intact 225 kD subunit and the increase of the native proteolytic fragments of 176 and 140 kD. Novel proteolytic fragments also became detectable. Using monoclonal antibody epitope mapping, it could be demonstrated that some of the proteolytic fragments corresponded in apparent molecular mass to those produced in vitro by incubating purified vWF with plasmin or elastase, but other fragments could not be attributed to these proteases. During the anhepatic and reperfusion stages there was a significant correlation between the degree of vWF degradation and the total amount of blood components transfused to replace blood losses. To evaluate whether or not vWF degradation could be controlled by the administration of a broad-spectrum protease inhibitor such as aprotinin, 5 patients were given a bolus dose of 500,000 U before surgery followed by 100,000 U/h during surgery, 5 were given a 2,000,000 U bolus followed by 500,000 U/h, and no aprotinin was given to the remaining 6 patients. There were no differences in the patterns or degrees of vWF degradation between patients treated with aprotinin or not. In conclusion, there is a marked degradation of a key hemostasis protein during OLT. These alterations may be of clinical significance, because they are correlated with the transfusion requirements.

• References

• 1 Porte RJ, Knot EAR, Bontempo FA. Hemostasis in liver transplantation. Gastroenterology 1989; 98: 488-501
• 2 Bismuth H, Ericson BG, Rolles K, Castaing D, Otte JB, Ringe B, Sloof M. Hepatic transplantation in Europe. First report of the European liver transplant registry. Lancet 1987; 2: 674-676
• 3 Dzik WH, Arkin CF, Jenkins RL, Stump DC. Fibrinolysis during liver transplantation in humans: role of tissue plasminogen activator. Blood 1988; 71: 1090-1095
• 4 Riess H, Jochum M, Machleidt W, Himmelreich G, Slama KJ, Steffen R. Possible role of the phagocytic proteinases cathepsin B and elastase in orthotopic liver transplantation. Transplant Proc 1991; 23: 1947-1951
• 5 Legnani C, Palareti G, Rodorigo G, Gozzetti G, Mazziotti A, Martinelli G, Zanello M, Sama C, Coccheri S. Protease activities, as well as plasminogen activators, contribute to the “lytic” state during orthotopic liver transplantation. Transplantation 1993; 56: 568-572
• 6 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-782
• 7 Mannucci PM, Lombardi R, Lattuada A, Ruggenenti P, Viganò GL, Barbui T, Remuzzi G. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenia purpura and the hemolytic uremic syndrome. Blood 1989; 74: 981-983
• 8 Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79: 38-44
• 9 Mannucci PM, Moia M, Rebulla P, Altieri D, Monteguardo J, Castillo R. Correlation of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 55-65
• 10 Federici AB, Falanga A, Lattuada A, Di RoccoN, Barbui T, Mannucci PM. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-transretinoic acid. Br J Haematol 1996; 92: 733-739
• 11 Verstraete M. Clinical applications of inhibitors of fibrinolysis. Drugs 1989; 29: 236-261
• 12 Federici AB, Tombesi S, Coppola R, Colibretti ML, Gobbi M, Albertini A, Mannucci PM. Preliminary characterization of monoclonal antibodies to vWF. Proceedings of the International Symposium on Plasma Proteins: Hemostasis, Thrombosis and Iron Proteins. 1990 p. 103
• 13 McFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-312
• 14 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIH/von Willebrand factor. Blood 1981; 57: 1140-1143
• 15 Berkowitz SD, Dent JA, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS. Epitope mapping of the von Willebrand factor subunits distinguishes fragment present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest 1987; 75: 524-531
• 16 Berkowitz SD, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 1988; 72: 1790-1796
• 17 Lombardi R, Mannucci PM, Segatchian MJ, Garcia VV, Coppola R. Alterations of factor Vlll/von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 1981; 49: 61-71
• 18 Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-1383
• 19 Monteagudo J, Reverter JC, Mateo D, Seoane R, Mazzara R, Escolar G, Pereira A, Castillo R, Visa J. and the Liver Transplantation Group. Intraoperative investigation of von Willebrand factor structure and function in orthotopic liver transplantation. Transplant Proc 1990; 22: 1531-1532
• 20 Atichartkam V, Marder VJ, Kirby EP, Budzynsky AZ. Effect of enzymatic degradation on the subunit compositions and biologic properties of human factor VIE. Blood 1978; 51: 281
• 21 Berkowitz SD, Nozaki H, Titani K, Murachi R, Plow KP, Zimmerman TS. Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease. Blood 1988; 72: 721-727
• 22 Gralnick HR, Williams S, McKeown L, Kramer W, Krutzsch H, Gorecki M, Pinet A, Garfinkel LI. A monomeric von Willebrand factor fragment, Leu-504 Ser-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX. Proc Natl Acad Sci USA 1992; 89: 7880-7884
• 23 Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 1987; 2: 1289-1291
• 24 Groh J, Welte M, Azad SC, Forst H, Pratschke T, Kratzer MAA. Does aprotinin affect blood loss in liver transplantation?. Lancet 1992; 340: 173
• 25 Furlan M, Robles R, Lämmle B. Partial characterization and purification of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234
• 26 Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformations and requires calcium ions. Blood 1996; 87: 4235-4244